Mineralys Therapeutics' CEO Sold Shares Worth $1.97 Million. Should Investors Avoid the Stock?
This clinical-stage biotech focused on hypertension therapies reported a notable insider sale, according to new SEC filings.
Source: www.fool.com
This clinical-stage biotech focused on hypertension therapies reported a notable insider sale, according to new SEC filings.